Fiona Adshead

Dr. Fiona Adshead

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JGJessica Griffiths
Jessica Griffiths
FAFiona Adshead
Fiona Adshead
RSRustam Al-Shahi Salman
Rustam Al-Shahi Salman
CACraig Anderson
Craig Anderson
EBEmma Bedson
Emma Bedson
PWPaula R Williamson
Paula R Williamson
Background: Clinical trials are fundamental to healthcare, however, they also contribute to anthropogenic climate change. Following previous work to develop and test a method and guidance to calculate the carbon footprint of clinical trials, we have now applied the guidance to 10 further UK and international, academically sponsored clinical trials to continue the identification of hotspots and opportunities for lower carbon trial design. Methods: 10 collaborating clinical trial units (CTUs) self-identified and a trial was selected from their portfolio to represent a variety of designs, health areas and interventions. Trial activity data was collated by trial teams across 10 modules spanning trial setup through to closure, then multiplied by emission factors provided in the guidance to calculate the carbon footprint. Feedback was collected from trial teams on the process, experience and ease of use of the guidance. Results: We footprinted 10 trials: 6 investigational medicinal product trials, 1 nutritional, 1 surgical, 1 health surveillance and one complex intervention trial. Six of these were completed and four ongoing (two in follow-up and two recruiting). The carbon footprint of the 10 trials ranged from 16 to 765 tonnes CO 2 e. Common hotspots were identified as CTU emissions, trial-specific patient assessments and trial team meetings and travel. Hotspots for specific trial designs were also identified. The time taken to collate activity data and complete carbon calculations ranged from 5 to 60 hours. The draft guidance was updated to include new activities identified from the 10 trials and in response to user feedback. Discussion: There are opportunities to reduce the impact of trials across all modules, particularly trial-specific meetings and travel, patient assessments and laboratory practice. A trial’s carbon footprint should be considered at the design stage, but work is required to make this common place.

20 May 2026 in Sustainable Chemistry and Pharmacy
Verified
Journal Article
Closed access
CMCaroline T.A. Moermond
Caroline T.A. Moermond
FAFiona Adshead
Fiona Adshead
SBStefan Berggren
Stefan Berggren
TBThea Skafte Böttcher
Thea Skafte Böttcher
Marco CinelliMarco Cinelli
Marco Cinelli
EWEmma Witteveen
Emma Witteveen

27 October 2026 in Journal of Medical Economics
Verified
Journal Article
Open access
FAFiona Adshead
Fiona Adshead
GXGeorgios Xydopoulos
Georgios Xydopoulos
VVVasileios Vasilopoulos
Vasileios Vasilopoulos
ABAlexandre Babin
Alexandre Babin
ABAmitava Banerjee
Amitava Banerjee
CFClélia-Elsa Froguel
Clélia-Elsa Froguel
Cardiovascular, renal, and metabolic (CVRM) conditions—including hypertension (HTN), chronic kidney disease (CKD), type 2 diabetes (T2D), heart failure (HF), obesity (OBS), and dyslipidemia (DLD)—s...

30 June 2026 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
PPPatricia Pascual
Patricia Pascual
ACAmanda Caudwell
Amanda Caudwell
SMStephanie De Man
Stephanie De Man
MLMichael Lally
Michael Lally
EDEdouard Desrumaux
Edouard Desrumaux
FAFiona Adshead
Fiona Adshead
Introduction The National Health Service is responsible for 4% of total greenhouse gas emissions in England and is committed to net zero carbon emissions and reduced carbon-intensive care practices. Self-treatable diseases represent significant avoidable healthcare resource utilisation, and the socio-economic value of self-care has been documented—self-care practices globally deliver savings of approximately $120 billion for healthcare systems and almost 41 billion productive days, gaining 22 million quality-adjusted life years each year. However, the impact on greenhouse gas emissions is poorly defined. This analysis investigated the effect of self-care on greenhouse gas emissions of the healthcare system in the UK, with a focus on self-care for allergies. Methods Three scenarios were used to evaluate the potential impact on greenhouse gas emissions of the substitution of all self-treatable healthcare visits by over-the-counter and self-care medication, and the potential and current impact of self-care medication was explored for allergic rhinitis. Scenario 1 evaluated the impact of self-care, if used for all self-treatable diseases. Scenario 2 and scenario 3 focused on, respectively, the use of self-care for the treatment of allergic rhinitis today and the potential future value if all eligible medication for allergic rhinitis was obtained over-the-counter. Avoidable greenhouse gas emissions were based on avoided primary care consultations and accident and emergency visits. Results Each scenario resulted in reductions in greenhouse gas emissions from 2030 to 3930 kilo tons (kt) carbon dioxide equivalent (CO2eq) (scenario 1), 330–1000 kt CO2eq (scenario 2), and 100–200 kt CO2eq (scenario 3). These reductions represent approximately 8–16% (scenario 1), 1–4% (scenario 2), and 0.5–1% (scenario 3) of total National Health Service carbon emissions. Conclusion This study confirmed the environmental aspect of the triple value of self-care (social, economic, and environmental), by showcasing how self-care can help to reduce greenhouse gas emissions by the healthcare system in the UK.